Clinical Trials | December 27, 2025
IRLAB launches Phase Ib Trial of IRL757 for Parkinson’s patients with Apathy
The multicenter study will enroll 75 patients across 16 sites in Germany, Bulgaria, Poland, and Spain
The multicenter study will enroll 75 patients across 16 sites in Germany, Bulgaria, Poland, and Spain
The therapy targets the LRRC15 protein and is designed for enhanced tumor penetration and differentiated anti-tumor activity in solid tumors with the highest unmet needs.
Xeureka will receive an upfront payment from UBE and will be eligible for milestone payments tied to future research progress
SandboxAQ will receive an upfront payment and could earn up to $200 million in milestone payments tied to preclinical, development, regulatory, and commercial achievements
The randomized, double-blind, placebo-controlled single ascending dose (SAD) study evaluated safety, tolerability, pharmacokinetics, and target engagement in 46 healthy participants
Alphyn is developing Zabalafin Hydrogel as the first therapy to simultaneously tackle the interconnected drivers of AD
More than five drug candidates from his team progressed to human trials including drugs like Rilematovir (Phase IIb), and Bedaquiline
The partnership also allows both companies to explore CR-001 and SKB105 as monotherapies and in combination
The company also revealed that MK-2214 has received Fast Track Designation from the U.S. Food and Drug Administration
Partnership combines MilliporeSigma’s chemistry and organoid expertise with Promega’s assay technologies
Subscribe To Our Newsletter & Stay Updated
